Login to get immediate access to this content.
LoginSpeaker: Ichiro Kinoshita, Japan
Abstract discussed:
- 849O - Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: results from the MYTHOS trial: Watch the presentation from ESMO 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published October 2024